Evidence map›Paper›PMID 33620584›Full record

ArticleNanoscale research letters2021

Fe(II) and Tannic Acid-Cloaked MOF as Carrier of Artemisinin for Supply of Ferrous Ions to Enhance Treatment of Triple-Negative Breast Cancer.

Zihaoran Li, Xinghan Wu, Wenyu Wang, Chengcheng Gai, Weifen Zhang, Wentong Li, Dejun Ding

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale research letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Applicability of Redirecting Artemisinins for New Targets.Global challenges (Hoboken, NJ) · 2023
    Review
  16. Article
  17. Review
  18. BioMOF-Based Anti-Cancer Drug Delivery Systems.Nanomaterials (Basel, Switzerland) · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zihaoran Li *Department of Pathology, Weifang Medical University, Weifang, 261053, China.
Xinghan Wu *Department of Pathology, Weifang Medical University, Weifang, 261053, China.
Wenyu WangCollege of Pharmacology, Weifang Medical University, Weifang, 261053, China.
Chengcheng GaiDepartment of Pathology, Weifang Medical University, Weifang, 261053, China.
Weifen ZhangCollege of Pharmacology, Weifang Medical University, Weifang, 261053, China.
Wentong LiDepartment of Pathology, Weifang Medical University, Weifang, 261053, China. liwentong11@163.com.
Dejun DingCollege of Pharmacology, Weifang Medical University, Weifang, 261053, China. dejunding@wfmc.edu.cn.ORCID http://orcid.org/0000-0001-7809-7963
Weifang Medical University · CN

Funding

Project of Shandong Province Higher Educational Science and Technology Program J18KA279Projects of Medical and Health Technology Development Program in Shandong province 2019WS590
6 · The paper itself

Abstract

Suppression of tumor development by inducing ferroptosis may provide a potential remedy for triple-negative breast cancer, which is sensitive to intracellular oxidative imbalance. Recently, artemisinin (ART) and its derivatives have been investigated as potential anticancer agents for the treatment of highly aggressive cancers via the induction of ferroptosis by iron-mediated cleavage of the endoperoxide bridge. Owing to its poor water solubility and limited intracellular iron content, it is challenging for further application in antitumor therapy. Herein, we developed ferrous-supply nano-carrier for ART based on tannic acid (TA) and ferrous ion (Fe(II)) coated on the zeolitic imidazolate framework-8 (ZIF) with ART encapsulated (TA-Fe/ART@ZIF) via coordination-driven self-assembly. Drug release experiments showed that ART was not nearly released in pH 7.4, while 59% ART was released in pH 5.0 after 10 h, demonstrating the excellent pH-triggered release. Meanwhile, a high level of intracellular ROS and MDA, accompanied with decreasing GSH and GPX4, displayed a newly developed nano-drug system displayed markedly enhanced ferroptosis. Compared with monotherapy, in vitro and vivo tumor inhibition experiments demonstrated higher efficiency of tumor suppression of TA-Fe/ART@ZIF. This work provides a novel approach to enhance the potency of ferroptotic nano-medicine and new directions for TBNC therapy.

Indexed as

ArtemisininFerroptosisMetal–organic frameworksReactive oxygen speciesTriple-negative breast cancer

Identifiers

PMID33620584
PMCPMC7902752
OpenAlexW3113627020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.